Active	Status	Sponsor type	Region	Phase	Filter
5 Active 3 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Forchetti, Concetta
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease	Recruiting	3	600	Japan, US	Remternetug (IV), LY3372993, Remternetug (SC), Placebo	Eli Lilly and Company	Alzheimer's Disease	10/25	10/26
ENVISION, NCT05310071: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease	Active, not recruiting	3	1512	Europe, Canada, Japan, US, RoW	Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo	Biogen	Alzheimer's Disease	12/25	10/26
NCT05026866: A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)	Recruiting	3	2600	Japan, US	Donanemab, LY3002813, Placebo	Eli Lilly and Company	Alzheimer Disease	11/27	11/27
PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease	Recruiting	2	282	Europe, Canada, US, RoW	GSK4527226, Placebo	GlaxoSmithKline, Alector Inc.	Alzheimer's Disease	12/26	05/29
Asada, Takashi
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease	Recruiting	3	600	Japan, US	Remternetug (IV), LY3372993, Remternetug (SC), Placebo	Eli Lilly and Company	Alzheimer's Disease	10/25	10/26